XML 97 R49.htm IDEA: XBRL DOCUMENT
v3.22.4

Commitments and Contingencies - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2021 | Apr. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021
Loss Contingencies [Line Items] |  |  |  |
Payments in equity, amount | $ 10.0 |  |  |
Common Stock [Member] |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Number of common stock issued |  |  |  | 399,680
Lonza DMSA |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Percentage of defer payments agreed for completion |  | 50.00% |  |
Amount recorded with respect to the potential future payments above the initial cash cap |  | $ 10.0 |  |
Number of common stock issued | 399,680 |  |  |
Public offering price per share | $ 25.02 |  |  |
Sutro Biopharma Inc [Member] |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Number of common stock issued |  |  | 167,780 |
Upfront Consideration |  |  | $ 22.5 |
Upfront Consideration in Cash |  |  | 10.0 |
Upfront Consideration in Cash After Agreement Date |  |  | 5.0 |
Option Exercise Price in Cash |  |  | 75.0 |
Additional Milestone Payments in Cash |  |  | 60.0 |
Accrued Commitment |  |  | 5.0 |
Fair Value on Date of Settlement |  |  | 8.0 |
Sutro Biopharma Inc [Member] | Common Stock [Member] |  |  |  |
Loss Contingencies [Line Items] |  |  |  |
Upfront Consideration |  |  | $ 7.5 |

X
- Definition Accrued commitment. + References No definition available. + Details
Name: | pcvx_AccruedCommitment
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Additional milestone payments in cash. + References No definition available. + Details
Name: | pcvx_AdditionalMilestonePaymentsInCash
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and manufacturing services agreement payments in equity. + References No definition available. + Details
Name: | pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value on Date of Settlement. + References No definition available. + Details
Name: | pcvx_FairValueOnDateOfSettlement
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option exercise price in cash. + References No definition available. + Details
Name: | pcvx_OptionExercisePriceInCash
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of payments completion agreed to defer. + References No definition available. + Details
Name: | pcvx_PercentageOfPaymentsCompletionAgreedToDefer
Namespace Prefix: | pcvx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront consideration. + References No definition available. + Details
Name: | pcvx_UpfrontConsideration
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront consideration in cash. + References No definition available. + Details
Name: | pcvx_UpfrontConsiderationInCash
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront consideration in cash after agreement date. + References No definition available. + Details
Name: | pcvx_UpfrontConsiderationInCashAfterAgreementDate
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248 + Details
Name: | us-gaap_GuaranteeObligationsMaximumExposure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pcvx_LonzaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pcvx_SutroBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |